Longeveron Inc. (LGVN)
1.62
0.01 (0.62%)
At close: Apr 24, 2025, 12:12 PM
0.62% (1D)
| Bid | 1.6 |
| Market Cap | 24.23M |
| Revenue (ttm) | 2.39M |
| Net Income (ttm) | -15.97M |
| EPS (ttm) | -2.62 |
| PE Ratio (ttm) | -0.62 |
| Forward PE | -1.18 |
| Analyst | Buy |
| Ask | 1.63 |
| Volume | 44,118 |
| Avg. Volume (20D) | 256,231 |
| Open | 1.64 |
| Previous Close | 1.61 |
| Day's Range | 1.60 - 1.62 |
| 52-Week Range | 0.77 - 6.40 |
| Beta | 0.38 |
About LGVN
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors. It is conducting Phase 1 and 2 clinical trials in various indications, such as aging frailty, a...
Industry Biotechnology
Sector Healthcare
IPO Date Feb 12, 2021
Employees 25
Stock Exchange NASDAQ
Ticker Symbol LGVN
Website https://www.longeveron.com
Analyst Forecast
According to 3 analyst ratings, the average rating for LGVN stock is "Buy." The 12-month stock price forecast is $10, which is an increase of 517.28% from the latest price.
Stock Forecasts1 month ago
-0.65%
Longeveron shares are trading higher after the com...
Unlock content with
Pro Subscription
8 months ago
+0.87%
Longeveron shares are trading higher after the company announced study results from the CLEAR MIND Phase 2a clinical trial of Lomecel-B in mild Alzheimer's disease, meeting its key objectives to advance data supporting a favorable benefit/risk profile.
